PDCD1 and colorectal carcinoma: Nivolumab, another PD-1 inhibitor, was granted accelerated approval in July 2017 for use in patients with metastatic CRC with MSI-H or dMMR who had progressed on a combination of fluoropyrimidine, oxaliplatin, and irinotecan based on the results from the Checkmate-142 trial (NCT02060188), which found an objective response rate (ORR) of 28% (95% CI, 17, 42) in pretreated patients and duration of responses lasting 6 months or greater in 67% (95% CI, 38, 88) of patients [4, 120].